Acadia Pharmaceuticals Licenses SAN711 from Saniona for Essential Tremor Treatment
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has entered into an exclusive worldwide license agreement with Saniona (OMX: SANION) for SAN711, a first-in-class, highly selective GABA A -α3 positive allosteric modulator. Acadia plans to develop SAN711 as a potential treatment for essential tremor, a neurological disorder characterized by involuntary shaking or trembling in various parts of the body. A Phase 2 study is expected to begin in 2026.
The agreement highlights Acadia’s commitment to addressing unmet needs in central nervous system disorders. “Essential tremor has seen little innovation for decades, and SAN711 offers a compelling opportunity to address this long-overlooked condition,” said Catherine Owen Adams, CEO of Acadia Pharmaceuticals.
Under the terms of the agreement, Acadia will pay Saniona $28 million upfront, with potential milestone payments totaling up to $582 million. Saniona will also be eligible for tiered royalties ranging from mid-single digits to low double digits on net sales of SAN711. Acadia will lead the clinical development, regulatory submissions, and commercialization of SAN711, while supporting Saniona’s ongoing Phase 1 study and preparations for Phase 2.
This partnership expands Acadia’s portfolio of innovative therapies targeting neurological and neuropsychiatric conditions, furthering its mission to bring transformative solutions to patients.
